Search the Newsreel

Shattuck Labs (NASDAQ:STTK) Shares Gap Up - Here's Why

Form 13D/A Shattuck Labs For: 20 July By Investing.com

This article from Investing.com announces the filing of a Form 13D/A for Shattuck Labs on July 20. It is a brief, factual report typical of financial news services. The article includes the stock symbol STTK, which saw a -9.43% change.

STTK stock trades steady as Shattuck Labs highlights cash position and clinical progress

Shattuck Labs (STTK) is maintaining a steady stock performance by focusing on its strong cash position and advancing its immunotherapy pipeline. The company reported a cash balance of $114 million in fiscal 2024, which is expected to fund operations into 2026. While revenue is …

Form 13D/A Shattuck Labs For: 17 July By Investing.com

Investing.com reports on a Form 13D/A filing for Shattuck Labs related to activities on July 17th. The article provides the filing information and notes the company's stock symbol STTK which showed a +6.51% increase. This brief news item does not offer further details or …

Redmile updates 9.9% Shattuck Labs (STTK) stake after July trades

Redmile Group, LLC, Jeremy C. Green, and Redmile Biopharma Investments II, L.P. have updated their ownership in Shattuck Labs, Inc. (STTK), reporting a combined beneficial ownership of 10,019,421 shares, or 9.9% of the class. This includes shares directly held and those issuable from pre-funded …

Shattuck Labs (Nasdaq:STTK) - Stock Analysis

Shattuck Labs, a clinical-stage biotechnology company, is analyzed based on its financial health, growth prospects, and recent developments. The company faces risks due to substantial shareholder dilution, declining earnings forecasts, and current unprofitability, but its stock has seen significant price increases over the past …